BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8146655)

  • 1. Binding and suppression of the Myc transcriptional activation domain by p107.
    Gu W; Bhatia K; Magrath IT; Dang CV; Dalla-Favera R
    Science; 1994 Apr; 264(5156):251-4. PubMed ID: 8146655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
    Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
    Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
    Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
    J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant Max protein, derived by alternative splicing, associates with c-Myc in vivo and inhibits transactivation.
    Arsura M; Deshpande A; Hann SR; Sonenshein GE
    Mol Cell Biol; 1995 Dec; 15(12):6702-9. PubMed ID: 8524235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation.
    Beijersbergen RL; Hijmans EM; Zhu L; Bernards R
    EMBO J; 1994 Sep; 13(17):4080-6. PubMed ID: 8076603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
    Blackwood EM; Eisenman RN
    Science; 1991 Mar; 251(4998):1211-7. PubMed ID: 2006410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
    Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
    J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc.
    Shrivastava A; Saleque S; Kalpana GV; Artandi S; Goff SP; Calame K
    Science; 1993 Dec; 262(5141):1889-92. PubMed ID: 8266081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts.
    Kohlhuber F; Hermeking H; Graessmann A; Eick D
    J Biol Chem; 1995 Dec; 270(48):28797-805. PubMed ID: 7499403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo.
    James L; Eisenman RN
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10429-34. PubMed ID: 12149476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Max: functional domains and interaction with c-Myc.
    Kato GJ; Lee WM; Chen LL; Dang CV
    Genes Dev; 1992 Jan; 6(1):81-92. PubMed ID: 1730412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional activation by Myc is under negative control by the transcription factor AP-2.
    Gaubatz S; Imhof A; Dosch R; Werner O; Mitchell P; Buettner R; Eilers M
    EMBO J; 1995 Apr; 14(7):1508-19. PubMed ID: 7729426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
    Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
    EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Myc-interacting proteins: a second Myc network emerges.
    Sakamuro D; Prendergast GC
    Oncogene; 1999 May; 18(19):2942-54. PubMed ID: 10378691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc.
    Desbarats L; Gaubatz S; Eilers M
    Genes Dev; 1996 Feb; 10(4):447-60. PubMed ID: 8600028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.
    Bousset K; Oelgeschläger MH; Henriksson M; Schreek S; Burkhardt H; Litchfield DW; Lüscher-Firzlaff JM; Lüscher B
    Cell Mol Biol Res; 1994; 40(5-6):501-11. PubMed ID: 7735324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo.
    Grandori C; Mac J; Siëbelt F; Ayer DE; Eisenman RN
    EMBO J; 1996 Aug; 15(16):4344-57. PubMed ID: 8861962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.